Donepezil 23 mg: An empty suit

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Donepezil 10 mg/day has been a modestly successful therapeutic agent for the palliative treatment of Alzheimer disease dementia. In 2011, seeking greater efficacy and an extension of the Aricept brand, a 23-mg formulation of donepezil was introduced. A large-scale trial, organized by Eisai, the sponsor, failed to show superiority in their primary analyses of donepezil 23 mg/day in patients with moderate to severe Alzheimer disease dementia vs 10 mg, but the published report used post hoc analyses to claim "statistically significant benefits." There was greater than a 3 times higher rate of gastrointestinal side effects with 23 mg of donepezil compared to 10 mg. Thus, not only does donepezil 23 mg/day increase the likelihood of unacceptable gastrointestinal side effects, it provides no clinical benefits. Aricept 23 mg is about 10 times more costly per pill than donepezil 10 mg.

Original languageEnglish (US)
Pages (from-to)352-355
Number of pages4
JournalNeurology: Clinical Practice
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Donepezil 23 mg: An empty suit'. Together they form a unique fingerprint.

  • Cite this